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 Endogenous estrogen and progesterone play central roles in breast 
development and breast cancer. There is substantial evidence from 
observational studies that hormone replacement therapy (HT) 
increases the risk of breast cancer in healthy women ( 1 ). For this 
reason, HT has been considered to be contraindicated for breast 
cancer survivors. However, compelling reasons have arisen for an 
empirical test of whether HT is safe for climacteric symptoms in 
women with previously treated breast cancer. First, there are now 
more breast cancer survivors with climacteric symptoms due to 
increased incidence of breast cancer and improved survival times 
after treatment. Second, many current systemic cancer treatments 
induce early menopause and climacteric symptoms that are difficult 
to manage by nonhormonal means. Third, it is possible that the 
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  Background  Hormone replacement therapy (HT) is known to increase the risk of breast cancer in healthy women, but 
its effect on breast cancer risk in breast cancer survivors is less clear. The randomized HABITS study, 
which compared HT for menopausal symptoms with best management without hormones among women 
with previously treated breast cancer, was stopped early due to suspicions of an increased risk of new 
breast cancer events following HT. We present results after extended follow-up. 
  Methods  HABITS was a randomized, non – placebo-controlled noninferiority trial that aimed to be at a power of 80% 
to detect a 36% increase in the hazard ratio (HR) for a new breast cancer event following HT. Cox models 
were used to estimate relative risks of a breast cancer event, the maximum likelihood method was used 
to calculate 95% confidence intervals (CIs), and   2 tests were used to assess statistical significance, with 
all  P values based on two-sided tests. The absolute risk of a new breast cancer event was estimated with 
the cumulative incidence function. Most patients who received HT were prescribed continuous combined 
or sequential estradiol hemihydrate and norethisterone. 
  Results  Of the 447 women randomly assigned, 442 could be followed for a median of 4 years. Thirty-nine of the 
221 women in the HT arm and 17 of the 221 women in the control arm experienced a new breast cancer 
event (HR = 2.4, 95% CI = 1.3 to 4.2). Cumulative incidences at 5 years were 22.2% in the HT arm and 8.0% 
in the control arm. By the end of follow-up, six women in the HT arm had died of breast cancer and six 
were alive with distant metastases. In the control arm, five women had died of breast cancer and four had 
metastatic breast cancer ( P = .51, log-rank test). 
  Conclusion  After extended follow-up, there was a clinically and statistically significant increased risk of a new breast 
cancer event in survivors who took HT. 
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mechanism whereby HT induces and promotes tumor growth in 
healthy women may be different from its ability to promote the 
growth of microdeposits of tumor cells in breast cancer survivors. 
 These questions regarding the potential beneﬁ ts and dangers of 
HT in women previously treated for breast cancer have triggered 
a series of observational studies and analyses of clinical case series 
whose results seemed reassuring in general in that they found no 
increased risk of breast cancer recurrence following HT. Indeed, a 
meta-analysis of eight observational studies ( 2 ) that included 3710 
women (among whom the HT users had taken HT for a mean of 
28 months and were followed for a mean of 57.1 months) showed 
a relative risk (RR) of breast cancer recurrence of 0.64 (95% conﬁ -
dence interval [CI] = 0.50 to 0.82) in users compared with nonusers 
( 2 ). However, to date, only three small randomized studies have 
been initiated to address the safety of conventional HT in women 
with a previous breast cancer ( 3 – 5 ). During the course of these 
studies, further evidence of the association between HT and breast 
cancer risk in women without a previous breast cancer was pro-
vided by data from a large randomized trial ( 6 ) and a large obser-
vational study ( 7 ). Speciﬁ cally, the prospectively randomized 
Women’s Health Initiative study ( 6 ) found an RR of 1.26 (95% CI = 
1.0 to 1.59) for breast cancer in HT users after a mean of 5.2 years 
of follow-up. Current users of HT at recruitment into the obser-
vational Million Women Study ( 7 ) also had increased risk of breast 
cancer compared with nonusers (RR = 1.66, 95% CI = 1.58 to 
1.75). 
 The HABITS (Hormonal Replacement After Breast Cancer —
 Is it Safe?) trial was initiated alongside two similar studies ( 3 – 5 ) to 
evaluate in a prospective randomized trial whether HT for meno-
pausal symptoms is safe in women with a previously treated breast 
cancer. The goal of this noninferiority trial was to recruit 1300 
women to exclude the possibility that 2 years of HT conferred a 
relative risk of a new breast cancer event that exceeded 1.36, as 
compared with best symptomatic treatment without hormones. At 
the time that the protocol was designed and the study centers were 
recruited, it was felt that the only realistic way to reach the study 
goals was to allow a pragmatic choice of type of HT, so a variety 
of types of HT were allowed, depending on the choice of the 
patient and her physician(s). 
 The HABITS trial was initiated in May 1997. The Data 
Monitoring and Safety Committee (DMSC) for the HABITS trial 
carried out a planned interim analysis designed to detect a harmful 
effect of HT in March 2001. In February 2002, the organizers of 
the HABITS trial and of a similar trial in Stockholm, Sweden ( 5 ), 
agreed to pool safety analyses and to use a joint DMSC. The joint 
DMSC performed two interim analyses — also, designed only to 
detect a harmful effect — with pooled data from the HABITS and 
Stockholm studies in December 2002 and October 2003. Following 
protocol, the DMSC discussed its ﬁ ndings with the steering com-
mittees of the HABITS and Stockholm studies when, in October 
2003, the combined estimate of the hazard ratio (HR) for recur-
rence with HT compared with recurrence without HT reached 1.8 
(95% CI = 1.03 to 3.1) and was thus statistically signiﬁ cantly larger 
than 1.0. However, there was a statistically signiﬁ cant heterogeneity 
between the studies, with HRs of 3.3 in the HABITS study and 0.82 
in the Stockholm study ( P = .02) ( 4 , 5 ). The DMSC recommended 
that the HABITS trial stop and that the Stockholm investigators 
consider the consequences of the safety analysis for their trial. 
 The HABITS steering committee terminated its study in 
December 2003 ( 4 ). At this time, 447 women had been recruited 
and randomly assigned. When preliminary results based on a 
median follow-up of 2 years were reported ( 4 ), 33 breast cancer 
events had occurred and the hazard ratio had reached 3.5 (95% 
CI = 1.5 to 7.4). Here, we report results from a median follow-up 
of 4 years and a total of 56 breast cancer events. 
 Subjects and Methods 
 Subjects and Recruitment 
 Women were eligible if they had previously completed primary 
treatment for breast cancer, including a complete removal of the 
tumor and axillary surgery, radiotherapy, and chemotherapy as 
stipulated by the local treatment guidelines. Concomitant treat-
ment with adjuvant tamoxifen, but not with aromatase inhibitors, 
was allowed. The protocol stipulated that the tumor should be a 
histopathologically confirmed stage 0 – 2 breast cancer with less than 
four involved axillary lymph nodes. The participants were required 
to be free of recurrence, to have no other cancer or serious disease, 
and to have no other contraindications to HT. Furthermore, it was 
 CONTEXT AND CAVEATS 
 Prior knowledge 
 The HABITS trial, on the effect of hormone replacement therapy 
(HT) on breast cancer risk among breast cancer survivors, was 
stopped in December 2003 after two large studies reported that HT 
increases risk of breast cancer among healthy women. In 2004, 
preliminary results from a median follow-up of 2 years were 
reported. 
 Study design 
 HABITS was a randomized, open-label noninferiority trial in which 
447 Scandinavian women were randomly assigned to either HT 
(most often, to continuous combined or sequential estradiol hemi-
hydrate and norethisterone) or to best symptomatic treatment 
without hormones. 
 Contribution 
 A total of 442 women could be followed for a median of 4 years. 
Women in the HT arm experienced new breast cancer events more 
than twice as often as women in the control arm (39 out of 221 vs 
17 out of 221; hazard ratio = 2.4, 95% confidence interval = 1.3 to 
4.2). The cumulative incidence of a new breast cancer event at 5 
years was estimated at 22.2% for the HT arm and at 8.0% for the 
control arm. 
 Implications 
 Clinicians and their patients should weigh the benefits of use of HT 
for postmenopausal symptoms with the increased risk for new 
breast cancer events. 
 Limitations 
 The time at which the trial was terminated, certain characteristics 
of the patient population, and the types of HT used each could 
influence the degree to which use of HT increases breast cancer 
risk. The study was not placebo controlled, and some judgments 
about disease recurrence can be subjective. 
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required that participating women have menopausal symptoms that 
both they and their doctors deemed to need treatment. Recruitment 
began in May 1997 and ended in December 2003, when the trial 
was stopped. 
 Local networks of oncologists, surgeons, and gynecologists 
recruited, randomly assigned, and followed the participants. 
Centers from the Scandinavian Breast Group (SBG), the 
International Breast Cancer Study Group (IBCSG), and the 
European Organization for Research and Treatment of Cancer 
(EORTC) participated in the study under the umbrella of the 
Breast International Group (BIG). Random assignment was done 
by telephone, mail, or fax to the study headquarters, which was 
located separately from the clinics at the Regional Oncological 
Center in Uppsala, Sweden. The allocation scheme was computer 
generated in blocks of eight and was stratiﬁ ed by participating 
center, use of HT before diagnosis of the original breast cancer, 
and treatment with tamoxifen. The block size was unknown to the 
participating clinicians. Full oral informed consent was required. 
The study was approved by the local ethics committees at each 
participating center. The full trial protocol is available at  http://
www.roc.se . The study was registered prospectively with  The  Lancet 
in 1997 (registry number 97/PRT/23). 
 Interventions 
 Women were randomly assigned to receive either HT or best 
symptomatic management without hormones. Acupuncture for 
relief of symptoms ( 8 ) was allowed, but the synthetic steroid tibo-
lone was not. Choice of the specific type of HT was directed by 
local practice. If there was no preferred specific therapy in a partic-
ular center, a sequential estrogen – progestagen combination was 
prescribed for women with an intact uterus whose last menstruation 
was within the past 2 years. A continuous combined regimen was 
prescribed for women 2 or more years past menopause. Medium-
potency estrogens alone (ie, estrogens effective in treating hot 
flashes, which have higher potency than those used to stimulate 
urogenital mucosa but substantially lower potency than those used 
in oral contraceptives) were prescribed for women who had under-
gone hysterectomy. HT was given for 2 years in the HT arm. The 
majority of centers prescribed a sequential or continuously com-
bined regimen of estradiol hemihydrate (E2) and norethisterone 
acetate (NETA) for women with an intact uterus or estradiol for 
women who had undergone hysterectomy. This was an open-label 
study. After 2 years, patients were asked to stop treatment. If seri-
ous withdrawal symptoms occurred, they were prescribed gradually 
decreased dosages over a 6- to 12-month period. 
 Follow-up and Endpoints 
 The protocol recommended that participants be followed by a 
breast cancer specialist at least twice yearly for the first 3 years 
after random assignment and continue to be followed by a breast 
cancer specialist at least annually for at least 5 years in total. We 
recommended that the patients receive mammograms every 12 – 24 
months or participate in routine mammographic screening with 
target intervals of 18 – 24 months. Participants were also required 
to be seen by a gynecologist every year. New breast cancer events, 
any other new cancer, compliance, and side effects of treatment 
were recorded prospectively. 
 The main endpoint for this study was the ﬁ rst occurrence of 
any new breast cancer event, including contralateral breast cancer. 
Death from breast cancer was considered to be an event, provided 
that it was not preceded by an overt clinical breast cancer event. 
Between March 2005 and May 2006, all participating physicians 
checked the medical records of all randomly assigned patients to 
ensure that the data reported to the study headquarters at the time 
of randomization were accurate, to report further data from the 
treatment of the initial breast cancer, to report on compliance and 
total time on HT, and to verify follow-up status. 
 A serious adverse event was deﬁ ned as any undesirable reaction 
to a drug or treatment that occurred within 8 weeks of stopping 
any study intervention and that resulted in death, a life-threatening 
condition, hospitalization, persistent disability, unexpected severe 
toxicity, congenital anomaly or birth defect, second cancer, or 
another health problem requiring medical intervention. Serious 
adverse events were to be reported within 24 hours to the study 
headquarters. 
 Statistical Methods 
 The study was designed as a noninferiority trial ( 9 ). Under the 
assumption that the benefits of HT may be outweighed by some 
risk, but not by risk exceeding one and a third times the risk without 
HT, the study was designed to have a power of 80% to detect at 
least a HR of 1.36 or higher for a new breast cancer event following 
random assignment to HT as compared with best symptomatic 
treatment without hormones. For this power, a total sample size of 
1300 women was needed for a one-sided log-rank test with a statis-
tical significance level of 5% (at HR = 1.36) assuming a median 
follow-up of 5 years and a 20% cumulative incidence of new breast 
cancer events over 5 years in the non-HT group. 
 In the present report, all analyses were performed according 
to intention-to-treat principles. The hazard ratio with a 95% 
conﬁ dence interval derived from Cox proportional models ( 10 ) 
was used as the measure of relative risk when comparing the 
number of events in patients randomly assigned to HT with 
those randomly assigned to the non-HT group. The propor-
tional hazards assumption was judged by comparing Kaplan –
 Meier plots of survival against log(log(survival)) for each group 
of randomly assigned patients and found to hold. The conﬁ dence 
intervals were estimated with the maximum likelihood method, 
and  P values for hazard ratios were derived from   2 tests. In the 
adjusted models, age was used as a continuous variable and 
binary variables (yes vs no) were used for hormone receptor 
positivity (either a positive estrogen receptor or progesterone 
receptor status or both), ongoing treatment with tamoxifen, 
prior treatment with HT before primary breast cancer diagnosis, 
and presence of axillary metastases. The absolute risk of a new 
breast cancer event was estimated with the cumulative incidence 
function, with non – breast cancer death as competing event ( 11 ). 
A statistical signiﬁ cance level of 5% (two-sided tests) was used 
throughout. 
 Results 
 We previously reported on follow-up of 345 women with at least one 
follow-up record for all 434 women registered as of September 2003 
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( 4 ). At that time, 26 women in the HT arm and seven in the non-HT 
arm had experienced a new breast cancer event. The present report 
includes the 442 women for whom follow-up data were available out 
of the 447 women who were included in the HABITS trial at its 
termination on December 17, 2003 ( Figure 1 ). As of December 
2006, after a median follow-up of 4 years, there were a total of 
39 breast cancer events in the HT arm and 17 in the non-HT arm. 
 Baseline Characteristics 
 The baseline characteristics of HABITS participants were similar 
in the two arms ( Table 1 ). The only notable difference was that 
more women in the HT arm than the non-HT arm had had hor-
mone receptor–positive cancer (62.3% vs 54.5%). The ages of the 
women at random assignment varied widely in both arms, as did the 
time interval between the first diagnosis of breast cancer and ran-
dom assignment. However, for 80% of the women in both arms, 
the time between first diagnosis and random assignment was 
between 7 months and approximately 8 years. A majority of the 
women were node negative when initially diagnosed. About half of 
the women were taking HT before diagnosis and treatment 
of breast cancer, but only 33.5% were taking tamoxifen at the time 
of random assignment ( Table 1 ). 
 Because the study was not blinded, we were concerned that 
more intensive follow-up in women who were prescribed HT 
could introduce an information bias. However, the number of 
follow-up physician visits was similar in both groups ( Table 1 ). 
 Exposure to HT 
 The monitoring of all medical records in 2005 – 2006 gave complete 
information on the type of HT treatment for 246 women (203 in 
 Table 1 .  Baseline characteristics in women with follow-up by 
randomization arm * 
 Characteristic HT arm Non-HT arm 
 No. with follow-up 221 221
 Follow-up in years, median (range) 4.1 (0.01 – 7.8) 4.0 (0.2 – 7.7) 
 Time in years between primary 
 treatment and randomization, 
 median (range)
2.1 (0.1 – 23.2) 2.2 (0.1 – 26.5) 
 Age in years, mean (range) 55.6 (42 – 75) 54.8 (38 – 74) 
 Node positive, No. (%) 44 (19.7) 42 (18.8) 
 Hormone receptor positive, No. (%) 139 (62.3) 122 (54.5) 
 Hormone receptor status unknown, 
 No. (%)
64 (28.7) 75 (33.5) 
 Breast preserved, No. (%) 127 (57.0) 126 (56.3) 
 On HT before diagnosis, No. (%) 115 (51.6) 115 (51.3) 
 On adjuvant tamoxifen at 
 randomization, No. (%)
75 (33.6) 75 (33.5) 
 Follow-up clinic visits for breast 
 cancer, median
6 6 
 *  HT = hormone replacement therapy (HT arm designates those randomized to 
HT but not necessarily compliant).  
the HT arm and 43 in the non-HT arm) and on the duration of HT 
treatment for 238 women (199 in the HT arm and 39 in the non-
HT arm;  Table 2 ). Most of the women who received HT were 
prescribed combined regimens. Of the 119 on a continuously com-
bined regimen (ie, 100 compliant women from the HT arm and 19 
noncompliant women from the control arm), 72 women were given 
2 mg E2 and 1 mg NETA (Kliogest) daily, and 15 were given 1 mg 
E2 and 0.5 mg NETA (Activelle) daily. Of the 61 on sequential 
regimens (53 from the HT arm and eight from the control arm), 38 
women were prescribed a 28-day cycle with 2 mg E2 on days 1 – 12, 
2 mg E2 plus 1 mg NETA on days 13 – 22, and 1 mg E2 on days 
23 – 38 (Trisekvens). For the 54 women exposed to estrogen only 
(47 from the HT arm and seven from the control arm), 20 women 
took 1 – 2 mg E2 (Estrofem) daily and 10 took 0.625 or 1.25 mg 
conjugated estrogens (Compremin) daily. All other preparations 
were taken by fewer than 10 women each. 
 Eleven women in the HT arm did not receive any HT, whereas 
43 in the non-HT arm received HT, about one-third of whom also 
changed the type of HT during the study ( Table 2 ). The median 
duration of HT use was around 2 years in both randomization 
groups, but there was a wide range of exposure times ( Table 2 ). 
However, of those who used HT during the trial, 90% used it for 
4 years or less and only 10% used it for less than 6 months. Among 
the 199 women in the HT arm who took HT and for whom we had 
complete information about HT treatment times, 64 (32%) 
changed medication once and 14 (7%) changed it two or more 
times ( Table 2 ). Although some women who were on HT when the 
trial was stopped continued taking it after the trial closure in 2003, 
no women without HT started taking it after the trial ended. 
 Risk of a New Breast Cancer Event 
 Thirty-nine women in the HT arm and 17 in the non-HT arm 
experienced one or more breast cancer events ( Figure 1 ). The major-
ity of first events in the HT arm were local recurrences or contralat-
eral breast cancers. By contrast, in the non-HT arm, similar numbers 
of women had local recurrences or new breast cancers as had distant 
 Figure 1 .  Diagram of patient ﬂ ow in the HABITS trial. HT = hormonal 
replacement therapy; ITT = intention to treat. 
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metastases. The absolute number of distant metastases as first event 
was similar in the two arms ( Figure 1 ). 
 All women in the HT arm who developed a breast cancer event 
had been exposed to HT. Five of the women with a breast cancer 
event in the non-HT arm had also taken HT after random assign-
ment. Nineteen women in the HT arm had a new breast cancer 
event after the 2-year follow-up period (when the treatment should 
have stopped according to protocol). Nine of these women had con-
tinued to use HT until the time of the event, and one had exposure 
until 4 months before the event. 
 Table 3 shows the hazard ratios for a new breast cancer event 
for women randomly assigned to HT vs no HT in this trial. Both 
the crude hazard ratio and the hazard ratio adjusted for use of HT 
before diagnosis of the original breast cancer, use of tamoxifen, and 
hormone receptor status show a statistically signiﬁ cantly elevated 
risk of a breast cancer event in the HT arm (HR = 2.4 [95% CI = 
1.3 to 4.2] and HR = 2.2 [95% CI = 1.0 to 5.1] for the crude and 
adjusted models, respectively). The subset analyses stratiﬁ ed by HT 
use before diagnosis, use of tamoxifen, hormone receptor status, 
and lymph node status at primary treatment for breast cancer did 
not provide clear indications of effect modiﬁ cation or interaction. 
The only notable difference between strata was for tamoxifen use, 
with a higher risk among women who were using tamoxifen at the 
start of the trial compared with women who were not on tamoxifen 
at the time of random assignment (HR = 4.7 [95% CI = 1.4 to 16.2] 
vs HR = 1.9 [95% CI = 1.0 to 3.6]). However, the conﬁ dence 
interval for women on tamoxifen was wide, and there was no clear 
statistical evidence that tamoxifen modiﬁ es the effect of HT (the 
 P value for interaction between HT and tamoxifen use was .11). 
 The cumulative incidences of a new breast cancer event at 2 years 
were 9.5% (95% CI = 5.5% to 13.5%) in the HT arm and 3.8% (95% 
CI = 1.2% to 6.4%) in the non-HT arm. The corresponding esti-
mates at 5 years were 22.2% (95% CI = 15.6% to 28.7%) in the 
HT arm and 8.0% (95% CI = 3.8% to 12.3%) in the non-HT arm. 
The absolute differences between the arms were thus 5.7% (95% 
CI = 3.5% to 7.9%) at 2 years and 14.2% (95% CI = 10.9% to 17.5%) 
at 5 years. The cumulative incidence curves ( Figure 2 ) show that the 
curves began to separate between 1 and 2 years of follow-up. 
 Risk Associated With Different Regimens 
 In a model of risk of a new breast cancer event among the women 
assigned to HT by type of HT, using continuously combined 
regimens as a reference category, we found no differences in risk 
across the main categories of HT use ( Table 4 ). However, the 
subsets were small and both the statistical power and precision (as 
illustrated by the wide confidence intervals) were limited. A mul-
tivariable analysis that included age at random assignment, nodal 
 Table 2 .  Exposure to different types of hormone replacement 
therapy preparations and times (months) of exposure by random-
ization arm in all women with follow-up * 
 HT exposure
HT arm 
(n = 221)
Non-HT arm 
(n = 221) 
 Never exposed, No. 11 178 
 Exposed, No. † 210 43 
 Median time (months) 
  exposed (min–max)
23 (0 – 80) 23 (1 – 62) 
 HT preparation, No. 
  (median)/min–max  
  Continuously combined 100 (24)/0 – 80 19 (22)/3 – 62 
  Sequential 53 (23)/0 – 68 8 (14)/2 – 46 
  Estrogen only 47 (20)/1 – 70 7 (30)/1 – 48 
  Other 3 (15)/12 – 30 9 (30)/12 – 35 
  Unknown type of preparation 7 0 
 HT regimen changed once, No. 64 11 
 Changed HT regimen two
  or more times, No.
14 3 
 *  HT = hormone replacement therapy; min = minimum; max = maximum. 
 †  The median and min – max exposure times are derived from those with full 
information on exposure times (199 in the HT arm and 39 in the non-HT arm). 
 Table 3 .  HRs with 95% CIs for risk of a new breast cancer event in 
the hormone replacement therapy group vs the non – hormone 
replacement therapy group according to intention to treat * ,† 
 Characteristic
No. of events 
(No. of women 
in subset) HR (95% CI)
 P value ‡ 
(  2 ) 
 All women 56 (442) 2.4 (1.3 to 4.2) .003 
 All women, adjusted 52 (416) 2.2 (1.0 to 5.1) .013 
 Hormone receptor 
 positive
37 (268) 2.6 (1.3 to 5.4) .009 
 Hormone receptor 
 negative
19 (174) 1.8 (0.7 to 4.8) .205 
 Tamoxifen 18 (153) 4.7 (1.4 to 16.2) .015 
 No tamoxifen 38 (289) 1.9 (1.0 to 3.6) .067 
 HT before 
 diagnosis
26 (230) 2.3 (1.0 to 5.3) .049 
 No HT before 
 diagnosis
26 (186) 2.2 (1.0 to 5.1) .061 
 Node negative 30 (282) 2.4 (1.1 to 5.4) .026 
 Node positive 18 (110) 2.3 (0.8 to 6.4) .117 
 *  HR = hazard ratio; CI = confidence interval; HT = hormone replacement 
therapy. 
 †  The adjusted model adjusts for hormone receptor status, nodal status at 
primary diagnosis, presence or absence of tamoxifen treatment, and 
exposure to HT before first breast cancer diagnosis. 
 ‡  All  P values are based on two-sided tests. 
 Figure 2 .  Cumulative incidence to ﬁ rst breast cancer event by intention 
to treat. Deaths by causes other than breast cancer are treated as 
competing events. There were 39 events in the HT arm and 17 in the 
non-HT arm. HT = hormonal replacement therapy. 
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status at primary diagnosis, and the use of tamoxifen during the 
trial did not alter the pattern seen in  Table 4 . Exposure to estro-
gen alone yielded a HR of 1.4 (95% CI = 0.55 to 3.3) as compared 
with exposure to a continuously combined regimen. 
 Distant Metastasis – Free and Overall Survival 
 By the end of follow-up, six women from the HT group had died 
of breast cancer and six were alive with distant metastases. For the 
non-HT group, five women had died of breast cancer and four were 
alive with distant metastases. The difference in distant metastasis –
 free survival was not statistically significant ( P = .51, log-rank test). 
Three women in the HT arm died of causes other than breast 
cancer, compared with none in the non-HT arm. 
 Serious Adverse Events 
 Eight serious adverse events were reported in the HT arm and five 
in the non-HT arm. However, one of the serious adverse events in 
the HT arm, a primary lung cancer, was deemed to have little 
probability of being related to the HT medication or any other 
trial intervention, and two other reported events, one thrombo-
phlebitis and one basal cell carcinoma of the skin, did not fulfill the 
criteria for serious adverse events. Therefore, an equal number of 
serious adverse events occurred in the two arms. The other events 
reported in the HT arm were one instance each of deep venous 
thrombosis, pulmonary embolism, and endometrial cancer and two 
instances of rapidly progressing breast cancer. The serious adverse 
events reported in the non-HT arm were one instance each of deep 
venous thrombosis, pulmonary embolism, and cerebrovascular 
stroke and two instances of rapidly progressing breast cancer. The 
women with vascular events in the non-HT arm did not use HT. 
 Discussion 
 After a median follow-up of 4 years, there was a statistically signifi-
cantly increased risk of a new breast cancer event in a group of 
women with a previously treated stage 0 – 2 breast cancer and without 
signs of active disease who were randomly assigned to HT for 
menopausal symptoms as compared with women treated with best 
symptomatic treatment without hormones. The relative risk — based 
on a total of 56 events in an intention-to-treat analysis — was 2.4, 
corresponding to a clinically highly relevant 14% absolute difference 
in the cumulative incidence of a new breast cancer event at 5 years. 
Because only 21 women in total were diagnosed with distant metas-
tases (or had died from breast cancer), it is impossible to either rule 
out or substantiate any effect of HT exposure on the risk of progres-
sion to lethal breast cancer. However, if the analysis of time to event 
had incorporated all breast cancer events and all deaths together, the 
results would have been even more unfavorable for the HT arm. 
 Patient compliance with the recommended treatments was 
high in the context of HT medication; nevertheless, a total of 12% 
of patients in the HT arm did not actually take HT, and many 
women took HT for more than the 2 years stipulated in the proto-
col. There was a nearly complete monitoring of all original medi-
cal records, and only ﬁ ve patients were lost to follow-up. This loss 
to follow-up was not dependent on randomization arm. 
 Our study has several potential limitations. Because it was open 
label and not placebo-controlled, there was a risk for a bias related 
to possibly more vigorous follow-up and diagnosis of events in the 
HT arm. However, as indicated by the number of follow-up visits, 
there were no signs of a more active search for local recurrences or 
metastases in either group. 
 Another threat to the validity of our ﬁ ndings is that the interim 
analysis may have revealed just a random increase in the difference 
in the rates of new breast cancer events between arms, because if 
the trial were erroneously terminated early on a random high, all 
other analyses could have been biased upward. The noninferiority 
design of the main trial and the design of the interim analyses to 
detect a difference also make it difﬁ cult to interpret both the statis-
tical signiﬁ cance levels of the interim analyses and the ﬁ nal results 
in a statistically stringent way due to multiple testing. However, it 
is clear that the accumulation of new breast cancer events contin-
ued in the HT arm beyond the ﬁ rst analysis. All women with breast 
cancer events assigned to the HT arm were exposed to HT, and 
ﬁ ve of the 17 women in the non-HT arm with a new breast cancer 
event were also exposed to HT. Half of the women with breast 
cancer recurrences beyond the recommended 2 years of treatment 
in the HT arm were exposed to HT close to the time of recurrence. 
Because the length of HT treatment in the HT arm varied consid-
erably, it is difﬁ cult to assess whether the increased risk in the HT 
arm declined shortly after HT exposure. The change from an HR 
of 3.5 in our ﬁ rst report to 2.4 in the present report could be attrib-
uted to termination of exposure to HT and/or to a random high 
found in the safety analysis. Nevertheless, the observed relation-
ships between HT exposure and occurrence of new breast cancer 
events make it unlikely that they are associated only by chance. 
 It is not surprising that the results from this randomized trial 
deviate from those in the observational series ( 2 ). The majority of 
the observational studies were not formal studies that could con-
trol sufﬁ ciently for bias and confounding. Even in the carefully 
designed observational study from Seattle ( 12 ) that studied the risk 
of breast cancer recurrence following HT among breast cancer 
survivors and found decreased risk for HT users compared with 
nonusers (HR = 0.50, 95% CI = 0.30 to 0.85), it was difﬁ cult to 
completely exclude selection bias. An important methodological 
problem in observational studies is to adjust for the effects of 
any pretreatment screening for metastases and restaging of those 
exposed to HT. Furthermore, reliable data on patterns of HT 
exposure are seldom available in the observational setting. In 
several of the case series ( 13 – 18 ), one or more of the investigators 
were also the patients’ physicians, which increases the risk that 
patients do not report back bad outcomes. 
 Although the Stockholm trial ( 5 ) and the HABITS trial were 
very similar in their basic design, their results are inconsistent. The 
 Table 4 .  HRs with 95% CIs for any breast cancer event * 
 Type of preparation (No. exposed) HR (95% CI) 
 Continuously combined (100) 1.0 (reference) 
 Sequential (53) 1.4 (0.6 to 2.9) 
 Estrogen (47) 1.4 (0.6 to 3.1) 
 Other (3) 4.3 (0.6 to 33.0) 
 *  HR = hazard ratio; CI = confidence interval. This unadjusted analysis was 
restricted to the hormone replacement therapy arm, with 221 women and 39 
events. Women exposed to the continuously combined regimen were used 
as the reference group. 
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Stockholm trial reported in 2005 ( 5 ), after a median of 4.1 years of 
follow-up, a total of 11 new breast cancer events and two breast 
cancer deaths among 188 women in the HT arm, with 13 new 
breast cancer events and four breast cancer deaths among 190 
women in the non-HT arm. Compliance with protocol treatment 
was high, with 77% of the women randomly assigned to the HT 
arm taking HT and only 10% of women in the control group tak-
ing HT. In contrast to the HABITS study, however, the relative 
risk associated with random assignment to the HT arm was not 
elevated (HR = 0.82, 95% CI = 0.35 to 1.9). In its third and ﬁ nal 
interim analysis, the DMSC common to both studies found a sta-
tistical heterogeneity between the studies ( P = .02 in a two-sided 
likelihood ratio test). 
 Variations in the design of the two studies may account for the 
discrepant ﬁ ndings. First, there was a higher proportion of women 
with node-positive breast cancer in the HABITS trial than in the 
Stockholm trial. Thus, the HABITS trial probably had a higher 
proportion of women with subclinical disease that could have 
been stimulated to grow by HT. Second, a higher proportion 
of the women in the Stockholm study were being treated with 
tamoxifen, which would theoretically confer protection from 
breast cancer recurrence. However, our own subset analyses by 
use of tamoxifen, by nodal status, and by type of HT did not show 
that any of these differences explain the different outcomes of 
the two studies. On the other hand, our subset analyses have low 
precision and power, and true underlying differences cannot 
be excluded. 
 A third possible reason for the different results between the 
HABITS trial and the Stockholm study is that in the HABITS 
trial the most commonly used HT regimens included a potent 
testosterone-like progestagen, NETA, either continuously or for 
at least 10 days of a 28-day cycle. By contrast, the Stockholm 
study was speciﬁ cally designed to keep doses of progestagen as 
low as possible and to use a naturally occurring progesterone, 
medroxyprogesterone acetate (MPA), instead of NETA. 
Furthermore, the Stockholm study recommended a sequential 
regimen for women younger than 55 years and a regimen for 
older women in which the addition of progesterone to estrogen 
was given only every third month. If the biology underlying 
development of a recurrence of breast cancer in the Stockholm 
and HABITS trials is similar to the biology of induction and pro-
motion of cancer in healthy women, then the difference in the 
preparations used may explain differences between the outcomes 
of the two studies. The addition of progestagens in HT has been 
found to increase the risk of breast cancer ( 6 , 7 , 19 – 21 ). There are 
also indications that NETA is associated with a higher risk of 
breast cancer than MPA, especially if continuous combined regi-
mens are used ( 21 , 22 ). 
 In the HABITS trial, the new breast cancer events in the HT 
arm were mainly local events, and there was no convincing evi-
dence for a higher breast cancer mortality associated with HT 
exposure. This preponderance of local events, and the lack of inﬂ u-
ence of HT on breast cancer mortality, may be related to a rela-
tively short follow-up in the HABITS trial, but it may also mirror 
the clinical experience from HT exposure in women without a 
previous breast cancer. The evidence from observational studies 
suggests that HT induces primarily local growth ( 1 ), particularly 
when progestagens are added to HT ( 21 , 23 ), which was the 
prevailing type of HT used in this trial. 
 The results of the HABITS trial indicate a substantial risk for a 
new breast cancer event among breast cancer survivors using HT. 
The risk elevation is in line with the evidence from observational 
studies ( 1 , 7 ) and randomized trials ( 6 ) that HT increases the risk 
of breast cancer in healthy women. Our results further suggest that 
HT not only induces and promotes breast cancer but may also 
stimulate the growth of tumor microdeposits in breast cancer sur-
vivors. However, the combined evidence from observational stud-
ies and the randomized data on risk following HT treatment 
among breast cancer survivors are conﬂ icting ( 2 ). Further data 
from randomized studies are needed to deﬁ ne both the impact of 
speciﬁ c types of HT regimens (eg, type of progestagen included, 
sequential or combined administration) and accompanying cir-
cumstances (eg, a certain type or stage of tumor, HT for a limited 
time or during tamoxifen treatment) on the risk of recurrence in 
breast cancer survivors following HT exposure. 
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